about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

5AM, Avid­i­ty, Fi­deli­ty lead $100M in­fu­sion in­to next-gen, tar­get­ed com­ple­ment ap­proach

4 years ago
Financing
Startups

FDA hits Hutchmed, Jun­shi drugs with CRLs — fur­ther clar­i­fy­ing its stance on Chi­na-on­ly da­ta

4 years ago
China
FDA+

Af­ter spear­head­ing his­toric Covid ef­fort, Pfiz­er vac­cine R&D chief Kathrin Jansen to re­tire

4 years ago
People

Your guide to phar­ma Q1 num­bers; Un­pack­ing top 15 R&D gi­ants; Se­cret PhI­II fail­ures; 'Weirdo sci­ence' and ...

4 years ago
Weekly

As­traZeneca un­veils plans for R&D cen­ter in Kendall Square — which will al­so be Alex­ion's new HQ

4 years ago
Pharma

Five years in­to neoanti­gen work, cash-strapped Geno­cea lays off staff as it looks for 's­trate­gic al­ter­na­tives'

4 years ago
People

Y-mAb­s' long­time CEO steps down abrupt­ly as FDA re­views sec­ond pe­di­atric can­cer drug

4 years ago
People

Eli Lil­ly throws down the gaunt­let in obe­si­ty race, chal­leng­ing No­vo Nordisk with new PhI­II read­out

4 years ago
R&D

With a buy­out, planned spin­out and late-stage read­outs, GSK promis­es this will be a land­mark year

4 years ago
Pharma

Am­gen kicks back I/O drug at cen­ter of $500M deal, leav­ing biotech part­ner alone to pon­der next steps

4 years ago
Deals

In wake of IL-2 shut­down, Nek­tar lets go of 500+ staffers as it promis­es a turn­around

4 years ago
People
R&D

Vi­vo Cap­i­tal pitch­es $60M to bring Ar­row­head­'s RNAi meds to Chi­na via joint ven­ture

4 years ago
Deals
China

Serv­ing as a 'gate­way,' Cam­bridge ven­ture in­vestor clos­es $300M sec­ond fund

4 years ago
Financing

End­points 20 un­der 40; Ver­dict on PI3K; Re­gen­eron goes dis­count shop­ping; $1.85B deal im­plodes; and more

4 years ago
Weekly

Will a biotech ri­val fi­nal­ly shake up Ab­b­Vie's $2B Botox cos­met­ic fran­chise? Re­vance will find out soon

4 years ago
FDA+

As­traZeneca show­cas­es 83% risk re­duc­tion for long-act­ing Covid-19 an­ti­body at 6-month analy­sis

4 years ago
Coronavirus

Cit­ing 's­trate­gic con­sid­er­a­tions,' Ab­b­Vie breaks off Parkin­son's deal with biotech part­ner

4 years ago
R&D

Covid-19 roundup: Poland re­fus­es to pay for more vac­cine dos­es, trig­ger­ing le­gal fight; Pfiz­er, Mod­er­na face more ...

4 years ago
Coronavirus

Rid­ing on wave of clin­i­cal tri­al re­forms, ma­chine learn­ing start­up bags $50M to cre­ate 'dig­i­tal twin­s'

4 years ago
Financing
Outsourcing

Aca­di­a's prized pain drug from $52M buy­out flops its first test

4 years ago
R&D

When OS is the 'ul­ti­mate safe­ty end­point': FDA lead­ers ques­tion sin­gle-arm tri­als amid scruti­ny of PI3K drugs for ...

4 years ago
FDA+

Hit by 2 more flops, Bris­tol My­ers and Nek­tar wind down IL-2/PD-1 pro­gram at the cen­ter of $3.6B deal

4 years ago
Deals

Zoom­ing in on a biotech lay­off; $1.9B buy­out to fill M&A void; Covid win­ners ap­point new fi­nance chiefs; and more

4 years ago
Weekly

Ab­b­Vie, Gen­mab tout ear­ly da­ta for bis­pe­cif­ic in a bid to leapfrog Re­gen­eron, Roche

4 years ago
R&D
First page Previous page 32333435363738 Next page Last page
A service from the Financial Times